Sarah Gualano, MD
Cardiovascular Disease · Brighton, MINPI 1487772844
Payments from drug & device makers
What this record shows
Medtronic accounts for 89.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $9,953 and has fallen 93.4% since, to $654 in 2025.
Across 217 payments — averaging $92.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Boston Scientific$668
- Abbott$519
- Edwards Lifesciences$340
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$285
- ZOLL Circulation Inc$189
- plus $194 from 2 others
What the payments were for
- Travel & lodging$11,37857%
- Food & beverage$8,61343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 197 | $17,797 |
| Boston Scientific | 5 | $668 |
| Abbott | 3 | $519 |
| Edwards Lifesciences | 5 | $340 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $285 |
| ZOLL Circulation Inc | 2 | $189 |
| Abiomed | 1 | $143 |
| E.r. Squibb & Sons, L.L.C. | 1 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$8,930
- Resolute$2,358
- CoreValve Evolut$2,288
- PORTICO$519
- GENERAL - THERAPIES$293
- GENERAL - STRUCTURAL HEART$242
- SAPIEN 3 Ultra RESILIA$189
- Impella$143
- GENERAL VASCULAR ACCESS$132
- TherOx DS2 Console$121
- Catheter$121
- Downstream Cartridge$121
- LifeVest$100
How this compares
$19,991 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 43 | $30,157 |
| Atorvastatin Calcium | 67 | $1,308 |
| Metoprolol Succinate | 45 | $1,086 |
| Rosuvastatin Calcium | 29 | $855 |
| Ezetimibe | 16 | $474 |
| ClopidogrelClopidogrel Bisulfate | 19 | $468 |
| Losartan Potassium | 26 | $348 |
| Lisinopril | 26 | $298 |
| Amlodipine Besylate | 13 | $192 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Brighton
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.